Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries... Show more
Avantor, a leading life science tools and services provider, has spent the past year working through its "Revival" transformation program after a prolonged stretch of declining organic revenue. The third quarter of 2026 represents a meaningful inflection point: it marked the first quarter in which the entire company returned to organic sales growth, building on the stabilization seen in the prior two quarters. For investors, this report matters because it tests whether Avantor's cost and commercial initiatives can convert a stronger demand environment into durable, profitable growth. The results also carry broader read-through for the life sciences supply chain, offering a window into research funding, pharma and biotech spending, and lab activity across global end markets.
For the third quarter ended September 30, 2026, Avantor posted net sales of $1.698 billion, a 4.6% reported increase and 5.2% organic growth from the prior-year period. Revenue exceeded analysts' consensus estimate of approximately $1.64 billion. Adjusted EPS of $0.22 topped the $0.21 consensus, while GAAP diluted EPS was $0.30, compared with a net loss of $711.8 million in the year-ago quarter that included a large impairment charge.
Segment performance was broad-based. VWR Distribution & Services generated $1.234 billion in revenue, up 5.8% organically, reflecting stronger commercial execution and healthier end markets. Bioscience & Medtech Products (BMP) returned to growth with revenue of $464.5 million, up 3.6% organically, ahead of management's expectations. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was roughly $257 million, a 15.1% margin. The company generated $156 million in free cash flow, or $169 million excluding cash restructuring costs, and reduced its adjusted net leverage ratio to 3.1 times from 3.3 times in the prior quarter.
Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for both active traders and longer-term investors seeking to refine their watchlists. Explore the AI Screener to put these capabilities to work in your own research process.
The market's response to Avantor's third-quarter results was measured. Although the company beat consensus on both revenue and adjusted EPS and raised its full-year outlook, shares fell about 2.5% to around $16.71 in early trading. That pullback reflected lingering concerns about profitability: adjusted EBITDA declined year over year, and consolidated margins remain below historical levels as faster growth in the lower-margin VWR distribution business weighs on the mix. With the stock having surged over the prior six months and trading near a 52-week high, some investors appeared to take profits even as the underlying results confirmed a genuine return to growth.
Following this report, the focus shifts to whether Avantor can sustain its recovery momentum and translate revenue growth into margin expansion. Management raised full-year 2026 guidance, now expecting organic revenue growth of 0.75% to 1.25%, adjusted EPS of $0.81 to $0.83, and free cash flow of $525 million to $550 million.
Investors should watch several factors in the months ahead. First, the December 8, 2026 Investor Day will be a key catalyst, as management is expected to provide more detail on 2027 expectations and the longer-term trajectory of the Revival program. Second, margin trends matter: the company must absorb inflationary pressures and an unfavorable product mix while continuing targeted growth investments. Third, geographic demand is uneven, with the Americas and Asia performing well while Europe lags amid budget and funding pressures.
Finally, balance sheet progress remains a priority. Management aims to reduce its adjusted net leverage ratio below 3.0 times by year end, and continued debt reduction could support the stock's valuation. As always, these are known drivers and milestones rather than guarantees, and future results will depend on execution and the broader health of life sciences end markets.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a manufacturer of laboratory chemicals
Industry PharmaceuticalsOther